Investor Resources
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M...
Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose...
Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications...
Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its...
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022....